1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europe. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
2. Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018;361:k1453. doi:10.1136/bmj.k1453
3. Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588-1597. doi:10.1161/CIRCULATIONAHA.117.028981
4. Allan V, Honarbakhsh S, Casas J-P, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837-850. doi:10.1160/TH16-11-0825
5. Lip GYH. The ABC pathway: An integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627-628. doi:10.1038/nrcardio.2017.153
6. Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol. 2020. doi:10.1038/s41569-020-00459-3
7. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol. April 2021. doi:10.1093/europace/euab065
8. Chao T-F, Joung B, Takahashi Y, et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost. 2022;122(1):20-47. doi:10.1055/s-0041-1739411
9. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665
10. Andrade JG, Verma A, Mitchell LB, et al. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2018;34(11):1371-1392. doi:10.1016/j.cjca.2018.08.026
11. Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
13. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638
14. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1-16. doi:10.1007/s40262-013-0100-7
15. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272. doi:10.1378/chest.09-1584
16. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134
17. Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2017;17(1):238. doi:10.1186/s12872-017-0672-5
18. Ha JT, Scaria A, Andrade J, et al. Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada. Kidney Med. 2023;5(7). doi:10.1016/j.xkme.2023.100675
19. Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolis. Circulation. 2014;130(2):138-146. doi:10.1161/CIRCULATIONAHA.113.005008
20. van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013;6(4):740-747. doi:10.1161/CIRCHEARTFAILURE.113.000212
21. Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibri. Am Heart J. 2015;170(4):675-682.e8. doi:10.1016/j.ahj.2015.07.006
22. Alberts MJ, He J, Kharat A, Ashton V. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy. Am J Cardiovasc Drugs. 2022;22(4):425-436. doi:10.1007/s40256-021-00520-7
23. Perales IJ, San Agustin K, DeAngelo J, Campbell AM. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Ann Pharmacother. 2020;54(4):344-350. doi:10.1177/1060028019886092
24. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med. 2010;363(26):2499-2510. doi:10.1056/NEJMoa1007903
25. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med. 2012;366(14):1287-1297. doi:10.1056/NEJMoa1113572
26. Konstantinides S V, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of. Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405
27. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051
28. Márquez-Contreras E, Martell-Claros N, Gil-Guillén V, et al. Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance. Qual life Res an Int J Qual life Asp Treat care Rehabil. 2017;26(3):647-654. doi:10.1007/s11136-016-1489-x
29. Guo Y, Kotalczyk A, Imberti JF, Wang Y, Lip GYH. Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Eur Hear journal Qual care Clin outcomes. 2023;9(2):169-176. doi:10.1093/ehjqcco/qcab054
30. Komen JJ, Pottegård A, Mantel-Teeuwisse AK, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. EP Eur. June 2021. doi:10.1093/europace/euab091
31. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. J Manag care Spec Pharm. 2016;22(11):1319-1329. doi:10.18553/jmcp.2016.22.11.1319
32. Miyazawa K, Ogawa H, Mazurek M, et al. Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. Circ J. 2019;83(12):2434-2442. doi:10.1253/circj.CJ-19-0546
33. Eur Heart J (2024) 00, 1–101, https://doi.org/10.1093/eurheartj/ehae176
34. Kreutz R et al. ACC. Washington, DC, USA, 2–4 April 2022. 2. Kreutz R, et al. A Real-World, prospective observational study to compare rivaroxaban versus vitamin K antagonist treatment in patients with non-valvular atrial Fibrillation and advanced chronic kidney disease. J Am Coll Cardiol 2022; 79 (9_Supplement) 201.
35. Hanon O et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation.!-leart 2020; doi:10.1136/heartjnl-2020-317923
36. Sameer Bansilal. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J2015 Oct;170(4):675-682.e8. doi: 10.1016/j.ahj.2015.07.006. Epub 2015 Jul 17.
37. Baker i wsp. Diabetes Obes Metab 2019; 21:2107-2114; retrospektywna analiza amerykańskiej bazy danych MarketScan z codziennej praktyki Xarelto (n=10 700) vs warfaryna (n=13 946).38. Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI..Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620954910. doi: 10.1177/1076029620954910.